440 Topical phosphodiesterase 4 (PDE4) inhibitor crisaborole (crisa) improves skin transcriptomic and proteomic biomarkers of mild-to-moderate AD towards normal skin

This study was conducted to identify changes in genomic and proteomic skin profiles of 40 patients with AD lesions treated with crisa, a nonsteroidal PDE4 inhibitor, and vehicle and compare them to those of nonlesional (NL) and normal (N) skin. 2 randomly assigned (1:1 intrapatient manner) target lesions were treated with crisa or vehicle BID for 14 days. Punch biopsies were collected from lesional and nonlesional skin from patients with AD and 20 healthy controls at baseline and days 8/15 of treatment.